Cure8 research brief
The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized approaches. It also highlights that blood tests may not reflect important tissue-level differences.
Researchers, clinicians, and adult patients interested in IBD immunology, biomarkers, or mucosal-based patient stratification
This study compared mucosal and blood immune cell profiles in patients with active Crohn’s disease (CD) and ulcerative colitis (UC) using a high-parameter cytometry panel on tissue and blood samples.
The authors identified many mucosal and circulating immune subsets and found distinct immune signatures between UC and CD: CD samples were largely T-cell biased, whereas UC showed a mixed infiltrate including increased NK, NKT and IgG+ B cells.
The paper reports that UC demonstrated substantially greater mucosal immune heterogeneity than CD when stratified by biological sex, age and endoscopic severity, suggesting that mucosal (tissue-resolved) profiling could be useful for patient stratification in UC.
The authors also note that blood-based biomarkers were less sensitive to these mucosal immune changes.
Structured content depth is abstract: the summary and conclusions are drawn from the article abstract and methods provided. This is a research study describing immunophenotyping findings; it does not by itself change clinical care or validate specific diagnostic tests or treatments.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.
